Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients
(World News USA)

39% ORR for G100+pembrolizumab is greater than either agent alone; reaches 57% ORR in the TLR4 patient population receiving G100+pembrolizumab (potential predictive biomarker) Responses occur in both recurrent/refractory and treatment-naïve patient populations Data presented at ASH 2017 Conference call Monday, December 11 at 8:00 a.m. EST SEATTLE and SOUTH SAN FRANCISCO, Calif., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today presented data from the randomized Phase 2 trial of its investigational intratumoral TLR4 agonist G100 plus low-dose radiation (G100 Monotherapy) with or without KEYTRUDA (pembrolizumab),...